KOD

Kodiak Sciences, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website kodiak.com
Employees(FY) 116
ISIN US50015M1099

Performance

+3.35%

+53.37%

+235.27%

+231.42%

+184.54%

YTD

+210.04%

Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Advanced Technical Analysis

Technical Analysis of KOD 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83, indicating robust upward momentum, while the Oscillators Score of 40 suggests a neutral stance, and the overall Technical Score of 61 reinforces a positive outlook. This combination implies that despite some neutral signals, the prevailing trend remains favorable fo...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of KOD

Stock Rank

Recent News & Updates

2024-12-10 10:43
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential(Zacks)
2024-12-09 13:26
Top Midday Gainers(MT Newswires)
2024-12-09 12:33
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock(Benzinga)
2024-12-09 11:43
Kodiak Sciences Shares Soar After Upgrade From Jefferies(MT Newswires)
2024-12-09 08:18
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases(Prnewswire)
2024-12-09 08:07
Jefferies Upgrades Kodiak Sciences to Buy From Hold, Raises Price Target to $20 From $6(MT Newswires)
2024-11-24 20:55
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?(Yahoo Finance)
2024-11-15 09:47
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus(Zacks)
2024-11-14 16:01
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results(PR Newswire)
2024-11-14 03:01
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results(Prnewswire)
2024-11-11 06:15
Kodiak Sciences to Participate in Upcoming Investor Conferences(PR Newswire)
2024-11-10 17:15
Kodiak Sciences to Participate in Upcoming Investor Conferences(Prnewswire)
2024-10-14 05:35
Kodiak Sciences to Present at Innovate Retina 2024(Prnewswire)
2024-09-22 18:00
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time(Prnewswire)
2024-09-17 04:05
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City(Prnewswire)
2024-09-12 23:30
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?(Yahoo Finance)
2024-08-15 22:42
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus(Yahoo Finance)
2024-08-14 09:54
KOD Stock Earnings: Kodiak Sciences Beats EPS for Q2 2024(Investorplace)
2024-08-14 04:01
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results(Prnewswire)
2024-07-10 00:00
All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy(Zacks)
2024-06-19 20:23
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?(Yahoo Finance)
2024-06-19 20:23
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?(Zacks)
2024-06-13 23:30
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?(Zacks)
2024-05-29 04:36
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences(Prnewswire)
2024-05-16 00:51
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus(Zacks)
2024-05-15 10:55
KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024(Investorplace)
2024-05-15 04:01
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results(Prnewswire)
2024-05-13 19:31
Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug(Yahoo Finance)
2024-05-13 07:32
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy(Prnewswire)
2024-05-02 04:30
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.